Why are unproven 'peptides' in the news, and how does the FDA treat them?

Unproven peptides are in the news because off-label and unapproved peptides became popular on social media in 2025 and 2026, while these peptides have unconfirmed safety and efficacy. A peptide is a short chain of amino acids, and some peptides are real, approved medicines. But a peptide structure alone is not enough information to determine effectiveness or safety. Liraglutide, a GLP-1 drug, is a peptide therapeutic, and unproven products are peptides too, which is why the word on its own tells you little. These products are the subject of dispute and this lesson only reports what sources and the FDA say.

BPC-157 is the best-known example. It is a synthetic peptide of fifteen amino acids derived from a protein in human gastric juice, discovered by Predrag Sikiric in Zagreb, Croatia, who published it in 1993. It has been studied mainly in laboratory animals and is not approved by any drug regulatory agency for human use. It became popular among athletes and the public for injury recovery, and the World Anti-Doping Agency banned it in 2022. A 2025 review found limited clinical evidence for it, including a retrospective study of 12 patients and a Phase I trial whose results were not submitted.

The regulators' message is cautious. On a page current as of 22 April 2026, the FDA said that for compounded drugs containing BPC-157 it lacks sufficient information to know whether the drug would cause harm in humans. It has also warned companies that sold unapproved drugs falsely labeled "for research purposes" or "not for human consumption".

The politics are live. One source reports that in July 2026 an FDA advisory panel, with six of its 14 members peptide sellers, advised the FDA to deregulate six peptides including BPC-157. What the FDA did next was not covered in the sources used here.